Literature DB >> 31256641

Prior hip or knee prosthetic joint infection in another joint increases risk three-fold of prosthetic joint infection after primary total knee arthroplasty: a matched control study.

B P Chalmers1, J T Weston1, D R Osmon2, A D Hanssen1, D J Berry1, M P Abdel1.   

Abstract

AIMS: There is little information regarding the risk of a patient developing prosthetic joint infection (PJI) after primary total knee arthroplasty (TKA) when the patient has previously experienced PJI of a TKA or total hip arthroplasty (THA) in another joint. The goal of this study was to compare the risk of PJI of primary TKA in this patient population against matched controls. PATIENTS AND METHODS: We retrospectively reviewed 95 patients (102 primary TKAs) treated between 2000 and 2014 with a history of PJI in another TKA or THA. A total of 50 patients (53%) were female. Mean age was 69 years (45 to 88) with a mean body mass index (BMI) of 36 kg/m2 (22 to 59). In total, 27% of patients were on chronic antibiotic suppression. Mean follow-up was six years (2 to 16). We 1:3 matched these (for age, sex, BMI, and surgical year) to 306 primary TKAs performed in 306 patients with a THA or TKA of another joint without a subsequent PJI. Competing risk with death was used for statistical analysis. Multivariate analysis was followed to evaluate risk factors for PJI in the study cohort.
RESULTS: The cumulative incidence of PJI in the study cohort (6.1%) was significantly higher than the matched cohort (2.6%) at ten years (hazard ratio (HR) 3.3; 95% confidence interval 1.18 to 8.97; p = 0.02). Host grade in the study group was not a significant risk factor for PJI. Patients on chronic suppression had a higher rate of PJI (HR 15; p = 0.002), with six of the seven patients developing PJI in the study group being on chronic suppression. The new infecting microorganism was the same as the previous in only two of seven patients.
CONCLUSION: In this matched cohort study, patients undergoing a clean primary TKA with a history of TKA or THA PJI in another joint had a three-fold higher risk of PJI compared with matched controls with ten-year cumulative incidence of 6.1%. The risk of PJI was 15-fold higher in patients on chronic antibiotic suppression; further investigation into reasons for this and mitigation strategies are recommended. Cite this article: Bone Joint J 2019;101-B(7 Supple C):91-97.

Entities:  

Keywords:  Complications; Contralateral; Prosthetic joint infection; Total hip arthroplasty; Total knee arthroplasty

Mesh:

Year:  2019        PMID: 31256641     DOI: 10.1302/0301-620X.101B7.BJJ-2018-1189.R1

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  4 in total

Review 1.  Perioperative management of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society for Rheumatology.

Authors:  Katinka Albrecht; Denis Poddubnyy; Jan Leipe; Philipp Sewerin; Christof Iking-Konert; Roger Scholz; Klaus Krüger
Journal:  Z Rheumatol       Date:  2022-03-02       Impact factor: 1.372

2.  [Perioperative management of treatment of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society of Rheumatology].

Authors:  Katinka Albrecht; Denis Poddubnyy; Jan Leipe; Philipp Sewerin; Christof Iking-Konert; Roger Scholz; Klaus Krüger
Journal:  Z Rheumatol       Date:  2021-12-20       Impact factor: 1.372

3.  One-year infection control rates of a DAIR (debridement, antibiotics and implant retention) procedure after primary and prosthetic-joint-infection-related revision arthroplasty - a retrospective cohort study.

Authors:  F Ruben H A Nurmohamed; Bruce van Dijk; Ewout S Veltman; Marrit Hoekstra; Rob J Rentenaar; Harrie H Weinans; H Charles Vogely; Bart C H van der Wal
Journal:  J Bone Jt Infect       Date:  2021-01-27

4.  Periprosthetic Joint Infection Caused by Gram-Positive Versus Gram-Negative Bacteria: Lipopolysaccharide, but not Lipoteichoic Acid, Exerts Adverse Osteoclast-Mediated Effects on the Bone.

Authors:  Mei-Feng Chen; Chih-Hsiang Chang; Chih-Chien Hu; Ying-Yu Wu; Yuhan Chang; Steve W N Ueng
Journal:  J Clin Med       Date:  2019-08-23       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.